Delcath Systems to Present at Canaccord Adams 29th Annual Global Growth Conference
11 August 2009 - 5:00AM
PR Newswire (US)
NEW YORK, Aug. 10 /PRNewswire-FirstCall/ -- Delcath Systems, Inc.
(NASDAQ: DCTH), a medical technology company testing its
proprietary treatment method for primary and metastatic cancers to
the liver, today announced its President and CEO Eamonn P. Hobbs
will make a presentation to investors at the Canaccord Adams 29th
Annual Global Growth Conference on Thursday, August 13 at 9:30 a.m.
Eastern Time in Boston. Mr. Hobbs will review the company's
business strategy and historic financial results. Attendance at the
conference is by invitation only. Delcath Systems will offer a live
webcast of its presentation and an archived replay available for 90
days at http://www.delcath.com/. About Delcath Systems, Inc.
Delcath Systems, Inc. is a medical device company specializing in
cancer treatment. The Company is testing a proprietary, patented
drug delivery system for the treatment of liver cancers. Delcath's
novel drug delivery platform is testing the delivery of ultra-high
doses of anti-cancer drugs to the liver while preventing these high
doses of drug from entering the patient's bloodstream. The Company
is currently enrolling patients in Phase III and Phase II clinical
studies for the treatment of liver cancers using high doses of
melphalan. The Company's intellectual property portfolio consists
of twenty-seven patents on a worldwide basis including the U.S.,
Europe, Asia and Canada. For more information, please visit the
Company's website at http://www.delcath.com/. DATASOURCE: Delcath
Systems, Inc. CONTACT: Investors, Doug Sherk or Stacey Fisher or
Mike Pollack, +1-415-896-6820, or Media, Steve DiMattia,
+1-646-201-5445, all of EVC Group, for Delcath Systems, Inc. Web
Site: http://www.delcath.com/
Copyright